Page last updated: 2024-10-30

leflunomide and Blindness

leflunomide has been researched along with Blindness in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Blindness: The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Neville, CE1
McNally, J1

Other Studies

1 other study available for leflunomide and Blindness

ArticleYear
Maternal exposure to leflunomide associated with blindness and cerebral palsy.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:9

    Topics: Adult; Antirheumatic Agents; Blindness; Cerebral Palsy; Female; Humans; Infant, Newborn; Isoxazoles;

2007